Longevity Global

We are excited to host the fourth annual Longevity Global Summit Dec. 3-4th at the Buck Institute for Research on Aging this year! Get early bird tickets while they last here: https://lnkd.in/gPw97FBw Big thanks to our sponsors: Calico Life Sciences, Hevolution Foundation, Altos Labs, Collaborative Drug Discovery - CDD Vault, Gero, BioAge Labs, Jevitty Life Science Corp., ICFSR CONGRESS Learn more and see our announced speakers at: https://lnkd.in/eMBPxUYT.

COVID’s Spike Protein Enhances Ability to Infect Brain A specific mutation in the SARS-CoV-2 spike protein increases its ability to infect the brain.

After 40 years of research emphasizing amyloid-beta (Aβ) as a primary culprit in Alzheimer's disease (AD), a groundbreaking study by the Jie Shen lab Yan et al. (2024) challenges this long-held assumption. Since Aβ's discovery in 1984, it has driven numerous drug developments, including therapies like lecanemab. Despite these efforts, patient decline persists with a less steep progression and risk ARIA. Yan et al. reveal that mutations in γ-secretase, cause neurodegeneration not through changes in Aβ, but due to a loss of PSEN1 function. This loss may lead to the depletion of critical cleavage products of other substrates or the buildup of unprocessed proteins, both of which could be targeted therapeutically. Interestingly, while Roche's RG6289, a γ-secretase modulator, shifts Aβ production toward shorter, potentially less "sticky" toxic forms, this approach might not fully address the potential issues with loss of γ-secretase activity. If this new result is correct, it will be essential to monitor the levels of other γ-secretase substrates as well as Aβ. This research not only opens up interesting possibilities for the future of Alzheimer’s therapy but also urges a careful re-evaluation of the current AD drug development pipeline.

Our next Longevity SF event will be on Brain Aging after work on September 30th. It will feature talks by yours truly and Salah Mahmoudi and the panel will be monitored by Chris Patil. Big thanks to BioAge Labs for sponsoring and MBC BioLabs for use of their beautiful space. Hope to see some folks there! RSVP: https://lu.ma/90qqi0eu

Check out our new article by Jonathan Algoo outlining new research on organ-specific biomarkers and their ability to help transform aging!

Did you know that dementia, which is incurable and currently counts for over one third of all deaths in seniors, may be preventable? https://lnkd.in/eczQZgrv

An NIA funded study found that a new blood test predicted the diagnosis of Alzheimer’s disease with 88% - 92% accuracy, which was shown to be more accurate than clinical evaluations done without biomarker-based testing. The study evaluated more than 500 older adults from local primary care clinics and nearly 700 from nearby specialty memory clinics. Using the PrecivityAD2 test, the researchers measured types of beta-amyloid and tau, hallmarks of the disease. Learn more about the study: https://lnkd.in/erb5ST33 #NIAFunded #NIHAging #Alzheimers #Tau217

Check out our new article by Jonathan Algoo outlining new research on organ-specific biomarkers and their ability to help transform aging!

R42 Demo Day! Every year Ronjon and R42 have a cohort of summer fellows that participate in projects on longevity, AI, market prediction and others. This year I'm excited to participate in the Longevity XPRIZE on the R42 team. An overview of that project from the fellows will be presented on Friday.

Save the date for multiple upcoming events from NIA! NIA is hosting several webinars covering climate and health, data accessibility and sharing, and health and aging trends: Aug 13: Learning From Examples: Trials and Tribulations Aug 21: Using Rush Alzheimer’s Disease Center-CMS Linked Data Sept 26: Using National Health and Aging Trends Study-CMS Linked Data Interested in learning more? Find details on these webinars and register today: https://lnkd.in/exhVJWij #NIHAging #AgingResearch #Webinar #ClimateChange #AlzheimersDisease